Everest Organics
Everest Organics (EVERESTO) share price was ₹258.00 at the 28 Oct 2026 close; market capitalisation ₹257 Cr; P/E (TTM) 47.69; sector Healthcare. The share price fell 36.5% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue fell 10.0% year on year to ₹48.43 Cr and net profit fell 21.3% year on year to ₹1.11 Cr (compared with Jun 2025). Promoters held 60.61% of Everest Organics in Sep 2026, up 1.01 percentage points from Jun 2026. Its Tapetide Score is 44/100 (Weak) as of 28 Oct 2026.
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of 29 Oct 2026, 10:32 IST · EPS basis: Standalone · TTM
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,763.60 | 34.99 | 4,23,147 Cr | 5.06 | 0.91% | 13.79% | 17.94% | 61,848 Cr | 12,117 Cr | |
| ₹9,678.50 | 87.84 | 2,56,934 Cr | 15.33 | 0.32% | 15.32% | 18.96% | 11,682 Cr | 2,925 Cr | |
| ₹4,588.30 | 72.03 | 1,74,524 Cr | 9.50 | 0.82% | 12.16% | 9.06% | 17,058 Cr | 2,156 Cr | |
| ₹2,195.10 | 108.45 | 1,18,604 Cr | 22.38 | 0.09% | 16.38% | 19.67% | 7,323 Cr | 1,090 Cr | |
| ₹1,183.20 | 26.33 | 1,18,025 Cr | 4.35 | 0.09% | 16.99% | 19.24% | 28,515 Cr | 4,593 Cr | |
| ₹1,338.80 | 34.67 | 1,11,747 Cr | 2.88 | 0.61% | 10.87% | 13.94% | 34,247 Cr | 3,184 Cr | |
| ₹1,365.20 | 32.71 | 1,10,289 Cr | 3.12 | 0.96% | 11.21% | 14.88% | 28,589 Cr | 3,356 Cr | |
| Everest Organics (this company) | ₹250.00 | 46.21 | 249 Cr | 3.14 | 0.20% | 7.35% | 16.64% | 192 Cr | 5 Cr |
| Median 8 companies | ₹1,564.40 | 40.60 | 1,18,314 Cr | 4.71 | 0.47% | 12.98% | 17.29% | 22,787 Cr | 3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Data confidence 100/100
Category scores
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Weaknesses
5- Stock is trading at 3.04 times its book value
- The company has delivered a poor sales growth of 1.56% over past five years.
- Company has a low return on equity of 2.49% over last 3 years.
- Company has high debtors of 216 days.
- Promoter holding has decreased over last 3 years: -14.6%
Technical Indicators
Oscillators
Bearish
Overall
Bullish
Moving Averages
Bullish
Growth Rate
change over 1 year
change over 1 year
change over 1 year
change over 1 year Operating margin 8.94% · Jun 2026
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 42.67 | 49.45 | 52.51 | 52.62 | 32.45 | 44.05 | 42.05 | 40.93 | 53.81 | 51 | 42.59 | 48.75 | 48.43 |
| Expenses | 40.15 | 46.74 | 49.71 | 49.67 | 36.11 | 40.62 | 38.03 | 37.49 | 49.37 | 45.87 | 39.05 | 42.05 | 44.1 |
| Operating Profit | 2.52 | 2.71 | 2.8 | 2.95 | -3.66 | 3.43 | 4.02 | 3.44 | 4.44 | 5.13 | 3.54 | 6.7 | 4.33 |
| OPM % | 5.91% | 5.48% | 5.33% | 5.61% | -11.28% | 7.79% | 9.56% | 8.4% | 8.25% | 10.06% | 8.31% | 13.74% | 8.94% |
| Other Income | 0.22 | 0.24 | 0.13 | 0.3 | 0.33 | 0.14 | 0 | 0.22 | 0.55 | 0.29 | 0.25 | 0.16 | 0.42 |
| Interest | 1.29 | 1.49 | 1.45 | 1.24 | 1.29 | 1.35 | 1.4 | 1.15 | 1.31 | 1.23 | 1.23 | 2.76 | 1.63 |
| Depreciation | 1.29 | 1.32 | 1.33 | 1.85 | 1.47 | 1.47 | 1.47 | 1.56 | 1.52 | 1.52 | 1.52 | 1.93 | 1.59 |
| PBT | 0.16 | 0.14 | 0.15 | 0.16 | -6.09 | 0.75 | 1.15 | 0.95 | 2.16 | 2.67 | 1.04 | 2.17 | 1.53 |
| Tax % | 75% | 78.57% | 93.33% | 62.5% | 0% | 1.33% | 0.87% | -206.32% | 35.19% | 56.93% | 65.38% | -21.2% | 26.8% |
| Net Profit | 0.04 | 0.03 | 0.02 | 0.06 | -6.09 | 0.74 | 1.14 | 2.91 | 1.41 | 1.16 | 0.36 | 2.63 | 1.11 |
| EPS (₹) | 0.05 | 0.04 | 0.02 | 0.08 | -7.61 | 0.92 | 1.42 | 3 | 1.45 | 1.19 | 0.37 | 2.71 | 1.14 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 106 | 99 | 107 | 112 | 156 | 167 | 182 | 200 | 183 | 197 | 159 | 196 | 191 |
| Expenses | 98 | 94 | 101 | 105 | 138 | 148 | 159 | 194 | 182 | 186 | 152 | 176 | 171 |
| Operating Profit | 8 | 6 | 6 | 7 | 18 | 19 | 23 | 6 | 1 | 11 | 7 | 20 | 20 |
| OPM % | 7% | 6% | 6% | 6% | 11% | 11% | 13% | 3.2% | 0.5% | 6% | 4.5% | 10% | 10% |
| Other Income | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 7 | 1 | 1 | 1 | 1 |
| Interest | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 5 | 5 | 7 | 7 |
| Depreciation | 3 | 3 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 6 | 6 | 6 | 7 |
| PBT | 2 | 0 | 2 | 2 | 12 | 14 | 17 | 2 | 0 | 1 | -3 | 8 | 7 |
| Tax % | 20% | 18% | 24% | 28% | 39% | 23% | 21% | 34% | 311% | 77% | -60% | 31% | — |
| Net Profit | 2 | 0 | 1 | 2 | 8 | 11 | 14 | 1 | 0 | 0 | -1 | 6 | 5 |
| EPS (₹) | — | 0.54 | 1.69 | 2.14 | 9.39 | 13.62 | 17.15 | 1.42 | -0.22 | 0.18 | -1.33 | 5.72 | 5.41 |
| Div. Payout % | 0% | 0% | 0% | 0% | 11% | 7% | 9% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 9 | 3 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 10 | 10 |
| Reserves | -3 | 3 | 8 | 11 | 18 | 26 | 39 | 39 | 38 | 38 | 60 | 66 |
| Borrowings | 24 | 28 | 19 | 22 | 21 | 18 | 23 | 39 | 51 | 58 | 48 | 50 |
| Other Liabilities | 37 | 42 | 51 | 54 | 60 | 68 | 66 | 92 | 105 | 123 | 106 | 114 |
| Total Liabilities | 67 | 76 | 86 | 94 | 107 | 120 | 135 | 178 | 202 | 227 | 223 | 240 |
| Fixed Assets | 24 | 27 | 33 | 34 | 38 | 39 | 44 | 49 | 54 | 52 | 50 | 46 |
| CWIP | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 8 | 12 | 21 | 23 | 22 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 42 | 47 | 52 | 60 | 68 | 80 | 92 | 121 | 136 | 153 | 150 | 171 |
| Total Assets | 67 | 76 | 86 | 94 | 107 | 120 | 135 | 178 | 202 | 227 | 223 | 240 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 4 | 7 | 10 | 5 | 9 | 10 | 14 | 14 | 18 | 16 | -5 | 4 |
| Investing | -3 | -7 | -8 | -4 | -5 | -6 | -12 | -17 | -16 | -13 | -5 | -2 |
| Financing | -2 | 0 | -2 | -1 | -3 | -3 | -2 | 2 | -3 | -3 | 16 | -8 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 1 | 0 | 0 | -1 | 0 | 0 | 6 | -6 |
| Free Cash Flow | 1 | 0 | 2 | 1 | 2 | 3 | 7 | -3 | 5 | 3 | -11 | 2 |
| CFO/OP | 52 | 119 | 162 | 64 | 50 | 51 | 59 | 214 | 1,981 | 149 | -76 | 21 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 100 | 117 | 105 | 124 | 95 | 97 | 102 | 125 | 152 | 185 | 202 | 216 |
| Inventory Days | 44 | 55 | 73 | 72 | 71 | 102 | 110 | 110 | 139 | 128 | 166 | 132 |
| Days Payable | 184 | 235 | 260 | 251 | 190 | 211 | 183 | 212 | 282 | 324 | 315 | 262 |
| Cash Conversion Cycle | -40 | -63 | -83 | -55 | -24 | -12 | 29 | 24 | 9 | -11 | 53 | 86 |
| Working Capital Days | -30 | -38 | -50 | -34 | -15 | 7 | 21 | 9 | -12 | -20 | 3 | 27 |
| ROCE % | 19% | 11% | 13% | 13% | 35% | 35% | 34% | 6% | 4% | 6% | 2% | 12% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Everest Organics insights
65 extracted metrics + investor summaries across FY10–FY27.
Documents
Frequently Asked Questions about Everest Organics
What does Everest Organics Ltd do?
Where is Everest Organics Ltd (EVERESTO) listed?
Which sector does Everest Organics Ltd belong to?
What is the market capitalisation of Everest Organics Ltd?
What is the PE ratio of Everest Organics Ltd?
What is the 52-week high and low of Everest Organics Ltd?
Does Everest Organics Ltd pay dividends?
What is the Return on Equity (ROE) of Everest Organics Ltd?
Company Information
Everest Organics Ltd (EOL) makes active pharmaceutical ingredients (APIs), the main medicinal ingredients in finished medicines, and chemical intermediates used to make APIs. Its factory is at Aroor, Sangareddy, Telangana.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524790.md for Everest Organics Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.